As the pharmaceutical industry moves deeper into 2026, one of the most consistent themes shaping sponsor decisions is the growing demand for reliable, high-quality U.S.-based API manufacturing. Supply chain resilience, regulatory confidence, and the need for flexible partners are all driving increased interest in domestic capabilities. At the center of this shift, Olon USA is entering the year with expanded capacity, high-potency development capabilities, and deeper integration within the global Olon Group network—positioning the organization as a strategic partner for both clinical and commercial API manufacturing programs.
A Major Investment in U.S. Commercial Manufacturing
At the company’s Concord, Ohio, facility, a significant capital investment is underway to expand higher-capacity commercial API manufacturing. This expansion is designed to support a major client program while also addressing the broader industry movement toward reshoring active pharmaceutical ingredient production back to the United States. Historically, the Concord site has been recognized for its strength in research and development manufacturing, including early-stage process development, scale-up, and clinical supply. The approval of two commercial drugs in 2025 marked a pivotal turning point, demonstrating the site’s ability to move programs from development into full commercial production. With the new investment, Olon USA is establishing a true commercial manufacturing footprint in the United States, giving sponsors a domestic option backed by global expertise and proven quality systems.
Importantly, this commercial expansion does not come at the expense of development and clinical manufacturing services. The Concord site continues to support programs from preclinical development through clinical phases and into commercial production, allowing sponsors to maintain continuity with a single manufacturing partner. This end-to-end capability is increasingly valuable in a market where speed, consistency, and regulatory confidence can significantly impact program timelines. By offering both clinical and commercial API manufacturing under one roof, Olon USA provides a scalable pathway that reduces the risks associated with technology transfers between sites.
High-Potency API Capabilities—Ready for GMP Development
One of the most notable capability expansions is the addition of a high-potency API manufacturing suite. The new containment environment supports development-scale manufacturing of high-potency compounds up to approximately 300 grams under both preclinical and GMP conditions. This capability is particularly relevant for oncology and targeted therapy programs, where high-potency APIs are increasingly common. Sponsors seeking a U.S.-based partner for high-potency process development, clinical supply manufacturing, or early GMP production can now leverage Olon USA’s contained suite along with the company’s broader process chemistry and scale-up expertise.
From Kilo Lab to Commercial Reality
Momentum is also building within the site’s kilo lab operations. Two customer programs manufactured at the Concord facility are expected to reach commercial production in 2026 or early 2027, and both will continue to be produced from the same kilo lab that supported their development. The facility has already successfully completed a Pre-Approval Inspection (PAI), providing sponsors with added confidence in regulatory readiness and manufacturing continuity. For companies navigating late-stage development or preparing for commercialization, the ability to maintain production within a proven, inspected environment can simplify supply chain planning and reduce regulatory risk.
Reshoring in Motion—And Built for It
These developments come at a time when the reshoring of API manufacturing is accelerating across the industry. Sponsors are actively evaluating domestic manufacturing partners who can provide both capacity and agility. Olon USA’s strength lies in its ability to pivot—whether that means adjusting the mix of clinical and commercial production or onboarding programs transitioning from overseas manufacturing. The organization’s culture of flexibility allows it to respond quickly to customer needs, while its integration within the global Olon network ensures access to additional expertise, technology, and capacity when required.
This global connection is particularly valuable for companies looking to transfer manufacturing back to the United States. Through its relationships with European and Indian sites within the Olon Group, Olon USA can support smoother technology transfers and onboarding processes. Sponsors benefit from consistent quality systems, aligned regulatory expectations, and coordinated project management across the network. The result is a more stable, resilient supply chain without sacrificing the advantages of global manufacturing expertise.
A New Era Since 2017
While the Concord facility has been operating since 1986, its identity has evolved significantly in recent years. Since joining the Olon Group in 2017, the site has been fully integrated into the organization’s global quality systems, operational standards, and strategic direction. The transition to the Olon USA name in early 2024 reflected that integration and signaled a new era for the site. Today, customers working with Olon USA experience the same quality culture, regulatory rigor, and technical depth that have made Olon a recognized API manufacturing partner worldwide.
As 2026 unfolds, the company is already seeing increased activity from sponsors who have secured funding and are ready to advance their programs. New contracts are being signed, development projects are coming online, and interest in U.S.-based API manufacturing continues to grow. For pharmaceutical and biotech companies seeking a partner capable of supporting preclinical development, clinical manufacturing, high-potency APIs, and commercial production—all within a globally integrated network—Olon USA is positioned as a strong, reliable option.
With expanded commercial capacity, high-potency capabilities, proven regulatory experience, and the backing of the global Olon organization, the message for 2026 is clear: Olon USA is not only prepared for the industry’s reshoring movement, but is also actively investing to lead it.